CNP Program
Primary Biliary Cholangitis (PBC)
Key Facts
About COUR Pharmaceuticals
COUR Pharmaceuticals is pioneering a novel approach to treating autoimmune diseases by addressing their root cause: the immune system's loss of self-tolerance. The company's proprietary COUR Nanoparticle Platform (CNP) delivers specific antigens to antigen-presenting cells in the liver and spleen, inducing durable, antigen-specific immune tolerance. With a diverse pipeline in development and in-house manufacturing capabilities, COUR aims to transform the standard of care for a wide range of immune-mediated conditions, moving beyond symptomatic relief to potentially disease-modifying therapies.
View full company profileAbout COUR Pharmaceuticals
COUR Pharmaceuticals is pioneering a novel approach to treating autoimmune diseases by addressing their root cause: the immune system's loss of self-tolerance. The company's proprietary COUR Nanoparticle Platform (CNP) delivers specific antigens to antigen-presenting cells in the liver and spleen, inducing durable, antigen-specific immune tolerance. With a diverse pipeline in development and in-house manufacturing capabilities, COUR aims to transform the standard of care for a wide range of immune-mediated conditions, moving beyond symptomatic relief to potentially disease-modifying therapies.
View full company profileAbout COUR Pharmaceuticals
COUR Pharmaceuticals is pioneering a novel approach to treating autoimmune diseases by addressing their root cause: the immune system's loss of self-tolerance. The company's proprietary COUR Nanoparticle Platform (CNP) delivers specific antigens to antigen-presenting cells in the liver and spleen, inducing durable, antigen-specific immune tolerance. With a diverse pipeline in development and in-house manufacturing capabilities, COUR aims to transform the standard of care for a wide range of immune-mediated conditions, moving beyond symptomatic relief to potentially disease-modifying therapies.
View full company profileAbout COUR Pharmaceuticals
COUR Pharmaceuticals is pioneering a novel approach to treating autoimmune diseases by addressing their root cause: the immune system's loss of self-tolerance. The company's proprietary COUR Nanoparticle Platform (CNP) delivers specific antigens to antigen-presenting cells in the liver and spleen, inducing durable, antigen-specific immune tolerance. With a diverse pipeline in development and in-house manufacturing capabilities, COUR aims to transform the standard of care for a wide range of immune-mediated conditions, moving beyond symptomatic relief to potentially disease-modifying therapies.
View full company profileTherapeutic Areas
Other Primary Biliary Cholangitis (PBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Setanaxib | Calliditas Therapeutics | Phase 2 |
| RO-7011789 (Nidufexor) | Rohto Pharmaceutical | Phase 2 |
| IQIRVO® (elafibranor) | Ipsen | Marketed / Late-stage Study |
| CNP-104 | Ironwood Pharmaceuticals | Preclinical |
| Elafibranor (GFT505) | Genfit | Phase 3 |